These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30309697)

  • 41. PCSK9 Inhibitors: Treating the Right Patients in Daily Practice.
    King P; Nicholls SJ
    Curr Cardiol Rep; 2017 Aug; 19(8):66. PubMed ID: 28643240
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
    Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White JA; Tershakovec AM; Blazing MA; Braunwald E
    Circulation; 2015 Sep; 132(13):1224-33. PubMed ID: 26330412
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [LDL-cholesterol control in patients with genetic dyslipidemia followed up by Lipid and Vascular Risk Units of the Spanish Society of Arteriosclerosis].
    Lahoz C; Mostaza JM; Pintó X; de la Cruz JJ; Banegas JR; Pedro-Botet J;
    Clin Investig Arterioscler; 2015; 27(1):1-8. PubMed ID: 24882148
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia.
    Pisciotta L; Sallo R; Rabacchi C; Wunsch A; Calandra S; Bertolini S
    Nutr Metab Cardiovasc Dis; 2012 Oct; 22(10):831-5. PubMed ID: 21920719
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia.
    Nherera L; Calvert NW; Demott K; Humphries SE; Neil HA; Minhas R; Thorogood M
    Curr Med Res Opin; 2010 Mar; 26(3):529-36. PubMed ID: 20014994
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia.
    Kawashiri MA; Nohara A; Noguchi T; Tada H; Nakanishi C; Mori M; Konno T; Hayashi K; Fujino N; Inazu A; Kobayashi J; Mabuchi H; Yamagishi M
    Am J Cardiol; 2012 Feb; 109(3):364-9. PubMed ID: 22112743
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel Approaches for the Treatment of Familial Hypercholesterolemia.
    Bonanni L; Cutolo A; Dalla Vestra M
    Exp Clin Endocrinol Diabetes; 2016 Nov; 124(10):583-587. PubMed ID: 27711959
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial.
    Cannon CP; Cariou B; Blom D; McKenney JM; Lorenzato C; Pordy R; Chaudhari U; Colhoun HM;
    Eur Heart J; 2015 May; 36(19):1186-94. PubMed ID: 25687353
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Autosomal recessive hypercholesterolaemia: normalization of plasma LDL cholesterol by ezetimibe in combination with statin treatment.
    Lind S; Olsson AG; Eriksson M; Rudling M; Eggertsen G; Angelin B
    J Intern Med; 2004 Nov; 256(5):406-12. PubMed ID: 15485476
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations.
    Adhyaru BB; Jacobson TA
    Curr Atheroscler Rep; 2017 Jun; 19(6):29. PubMed ID: 28500517
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Low daily dose of 3 mg monacolin K from RYR reduces the concentration of LDL-C in a randomized, placebo-controlled intervention.
    Heinz T; Schuchardt JP; Möller K; Hadji P; Hahn A
    Nutr Res; 2016 Oct; 36(10):1162-1170. PubMed ID: 27865358
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin.
    Fazio S; Robertson DG; Joh T; Wan H; Riel T; Forgues P; Baum CM; Garzone PD; Gumbiner B
    Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29057618
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Severe familial hypercholesterolemia treatment].
    Vrablík M; Freiberger T; Bláha V; Češka R
    Vnitr Lek; 2016; 62(11):895-901. PubMed ID: 28128576
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.
    Raal FJ; Hovingh GK; Blom D; Santos RD; Harada-Shiba M; Bruckert E; Couture P; Soran H; Watts GF; Kurtz C; Honarpour N; Tang L; Kasichayanula S; Wasserman SM; Stein EA
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):280-290. PubMed ID: 28215937
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Monacolin K supplementation in patients with hypercholesterolemia: A systematic review of clinical trials.
    Liasi E; Kantilafti M; Hadjimbei E; Chrysostomou S
    Semergen; 2024; 50(4):102156. PubMed ID: 38310834
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapeutic targets in the treatment of dyslipidaemias: From statins to PCSK9 inhibitors. Unmet needs.
    López-Miranda J; Pedro-Botet J
    Clin Investig Arterioscler; 2021 May; 33 Suppl 1():46-52. PubMed ID: 33966813
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New Drugs for Lowering LDL-Cholesterol.
    Bădescu C; Rezuş E; Bădescu L; Dima N; Rezuş C
    Rev Med Chir Soc Med Nat Iasi; 2016; 120(3):485-90. PubMed ID: 30044561
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical profile of patients treated with evolocumab in lipid/internal medicine units of Spain. Observational study (RETOSS-IMU).
    Masana L; López Miranda J; Civeira F; Reinares L; Guijarro C; Plana N; Cuenca R; Sánchez D; Hernández JL; Andrés R; Blanco A; Villamayor S
    Clin Investig Arterioscler; 2020; 32(5):183-192. PubMed ID: 32317124
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Hyperlipidemia: What role do PCSK9 inhibitors play?].
    Meyer D; Merkel M
    Dtsch Med Wochenschr; 2018 Oct; 143(20):1430-1434. PubMed ID: 30286489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.